北京博恩特药业

Beijing Boente Pharmaceutical is a specialized pharmaceutical company focused on the research, development, and commercialization of high-end sustained-release injectable formulations. The company is a leader in microsphere drug delivery technology in China, with its primary product, Leuprorelin Acetate Microspheres (Boennuokang), widely used in the treatment of hormone-sensitive cancers and gynecological disorders. Boente's expertise lies in overcoming the technical barriers of complex formulation manufacturing, ensuring stable drug release over extended periods. The company maintains a robust GMP-compliant production base in Beijing and targets therapeutic areas including oncology, urology, and endocrinology. Its portfolio includes both one-month and three-month sustained-release formulations, providing improved patient compliance for chronic conditions.